Royal Navy AW159 Wildcat completes missile tests at sea
This the first time the Martlet LMM has been launched on frontline operations by the RN. (Photo: UK MoD/Crown Copyright)
During operations in the Pacific Ocean as part of Carrier Strike Group 21, the RN AW159 Wildcat HMA has completed a new round of trials with the Martlet and Sea Venom air-to-surface missiles.
In the month-long trial, ending in the middle of October, the AW159 was operated from RFA Argus from where it was flown for 19 days for a total of 87 flight hours.
During operations, the helicopter test-fired a Thales Martlet lightweight multirole missile (LMM) at an inflatable target.
The initial firing of the LMM from an RN AW159 took place in May 2020, but this was the first time
Already have an account? Log in
Want to keep reading this article?
More from Air Warfare
-
Anduril UK and GKN Aerospace collaborate on British Army ACP bid
The pair will submit their demonstrator concept for Project Nyx, a development project for the British Army’s Land Autonomous Collaborative Platform.
-
US Army command’s Picatinny CLIK common lethal drone interface makes progress
The Picatinny Common Lethality Integration Kit is designed to overcome the issue of unique integration methods between lethal payloads and drones as well as avoiding problematic acquisition conditions created by vendor lock.
-
Australia invests extra A$1.4 billion in MQ-28A Ghost Bat after successful missile fire test
The investment includes new contracts for six MQ-28A Ghost Bat aircraft, as well as provisional funds to invest in the development of a Block 3 prototype.
-
US approves potential $4.7 billion missile and air defence system sales to Denmark and Italy
Italy could field the JASSM-ER for its combat aircraft including the F-35, while Denmark has been approved for AMRAAM and an Integrated Battle Command system procurement.
-
Northrop Grumman to fly new Project Talon CCA by late 2026
The newly unveiled collaborative combat aircraft looks to strike a balance between capability and cost-effectiveness, according to the company.